Pragmatic issues in biomarker evaluation for targeted therapies in cancer
作者： Armand De Gramont , Sarah Watson , Lee M Ellis , Jordi Rodón , Josep Tabernero
DOI: 10.1038/NRCLINONC.2014.202
关键词:
摘要: Biomarkers that predict a patient's responsiveness to anticancer therapies are of increasing importance during drug development and in clinical trials, as well the clinic. In this Review, major challenges biomarker standardization discussed, considerations for validation pre-analytical, analytical post-analytical protocols involved assays highlighted.
nature.com
sci-hub.se 参考文章(178)
Colin J. Davidson, Emily Zeringer, Kristen J. Champion, Marie-Pierre Gauthier, Fawn Wang, Jerry Boonyaratanakornkit, Julie R. Jones, Edgar Schreiber, Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection. BioTechniques. ,vol. 53, pp. 182- 188 ,(2012) , 10.2144/000113913
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework* Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 89- 95 ,(2001) , 10.1067/MCP.2001.113989
Assessing EGFR mutations. The New England Journal of Medicine. ,vol. 354, pp. 526- ,(2006) , 10.1056/NEJMC052564
Martin R. Berger, Ulrich Linnemann, Carl C. Schimanski, Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Research. ,vol. 59, pp. 5169- 5175 ,(1999)
C. Ted Rigl, Kevin C. Halling, Glenda G. Anderson, Fabiola Medeiros, Shawn H. Becker, Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Archives of Pathology & Laboratory Medicine. ,vol. 131, pp. 1805- 1816 ,(2007) , 10.1043/1543-2165(2007)131[1805:THFGEA]2.0.CO;2
Bianca Mostert, Yuqiu Jiang, Anieta M. Sieuwerts, Haiying Wang, Joan Bolt-de Vries, Katharina Biermann, Jaco Kraan, Zarina Lalmahomed, Anne van Galen, Vanja de Weerd, Petra van der Spoel, Raquel Ramírez-Moreno, Cornelis Verhoef, Jan N.M. IJzermans, Yixin Wang, Jan-Willem Gratama, John A. Foekens, Stefan Sleijfer, John W.M. Martens, KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue International Journal of Cancer. ,vol. 133, pp. 130- 141 ,(2013) , 10.1002/IJC.27987
Kelly B. Engel, Helen M. Moore, Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Archives of Pathology & Laboratory Medicine. ,vol. 135, pp. 537- 543 ,(2011) , 10.1043/2010-0702-RAIR.1
F. Bibeau, H. Frugier, A. Denouel, J.-C. Sabourin, F. Boissiere-Michot, Aspect technique de la détermination du statut KRAS dans le cancer colorectal et mise en place en France. Point de vue de l’anatomopathologiste Bulletin Du Cancer. ,vol. 96, pp. 15- 22 ,(2009) , 10.1684/BDC.2009.0993
Heidi Schwarzenbach, Dave S. B. Hoon, Klaus Pantel, Cell-free nucleic acids as biomarkers in cancer patients Nature Reviews Cancer. ,vol. 11, pp. 426- 437 ,(2011) , 10.1038/NRC3066
Miguel Martin, Jacques Bonneterre, Charles E. Geyer, Yoshinori Ito, Jungsil Ro, Istvan Lang, Sung-Bae Kim, Caroline Germa, Jennifer Vermette, Kenneth Wang, Kongming Wang, Ahmad Awada, A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer European Journal of Cancer. ,vol. 49, pp. 3763- 3772 ,(2013) , 10.1016/J.EJCA.2013.07.142